Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 162-171 , April 2004

Role of nutrition for cardiovascular risk reduction in chronic kidney disease patients

  • T Alp Ikizler

      Affiliations

    • Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA
    • Corresponding Author InformationAddress correspondence to T. Alp Ikizler, MD, Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Avenue, South & Garland, S-3223 MCN, Nashville, TN 37232-2372 USA

References 

  1. USRDS . Excerpts from United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis. 1999;34:S1–S176
  2. USRDS . Excerpts from the USRDS 2001 Annual Data Report. Am J Kidney Dis. 2001;38:S1–S248
  3. Locatelli F, Bommer J, London GM, et al.  Cardiovascular disease determinants in chronic renal failure (Clinical approach and treatment). Nephrol Dial Transplant. 2001;16:459–468
  4. Ikizler TA. Epidemiology of vascular disease in renal failure. Blood Purif. 2002;20:6–10
  5. Lowrie EG, Lew NL. Death risk in hemodialysis patients (The predictive value of commonly measured variables and an evaluation of death rate differences between facilities). Am J Kidney Dis. 1990;15:458–482
  6. Cheung AK, Sarnak MJ, Yan G, et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362
  7. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease (A new paradigm). Am J Kidney Dis. 2000;35:S117–S131
  8. Wanner C, Zimmermann J, Schwedler S, et al.  Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002;61:99–102
  9. Bergstrom J, Lindholm B, Lacson E, et al.  What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?. Semin Dial. 2000;13:163–175
  10. Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality (An integrated point of view). Am J Kidney Dis. 1998;32:834–841
  11. Health Care Financing Administration . 1994 Annual Report (Opportunities to improve care for adult in-center hemodialysis patients). 2004; Available at: http://www.cms.hhs.gov/esrd. Accessed March 10
  12. Health Care Financing Administration . 1999 Annual Report (ESRD Clinical Performance Measures Project). 2004; Available at: http://www.cms.hhs.gov/esrd. Accessed March 10
  13. Qureshi AR, Alvestrand A, Danielsson A, et al.  Factors predicting malnutrition in hemodialysis patients (A cross-sectional study). Kidney Int. 1998;53:773–782
  14. Bergstrom J. Protein catabolic factors in patients on renal replacement therapy. Adv Exp Med Biol. 1989;260:1–9
  15. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995;6:1329–1341
  16. Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis. 1993;21:125–137
  17. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int. 1996;50:343–357
  18. Kopple JD. Causes of catabolism and wasting in acute or chronic renal failure. In:  Robinson RR editors. Nephrology. (ed 2). New York, NY: Springer Verlag; 1984;p. 1498–1515
  19. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis. 1994;24:1002–1009
  20. Mitch WE, Goldberg AL. Mechanism of muscle wasting (The role of ubiquitin-proteasome pathway). N Engl J Med. 1997;335:1897–1905
  21. Mitch WE, Walser M. Nutritional therapy of the uremic patient. In:  Brenner BM,  Rector FC editor. The Kidney. (ed 4). Philadelphia, PA: Saunders; 1991;p. 2186–2222
  22. Pupim LB, Ikizler TA. Uremic malnutrition (New insights into an old problem). Semin Dial. 2003;16:224–232
  23. Ikizler TA, Wingard RL, Harvell J, et al.  Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients (a prospective study). Kidney Int. 1999;55:1945–1951
  24. Kimmel PL, Phillips TM, Simmens SJ, et al.  Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54:236–244
  25. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–636
  26. Stenvinkel P, Heimburger O, Paultre F, et al.  Strong association between malnutrition,inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  27. Zimmermann J, Herrlinger S, Pruy A, et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
  28. Bistrian BR. Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD. Am J Kidney Dis. 1998;32:S113–S117
  29. Kaysen GA. The microinflammatory state in uremia (Causes and potential consequences). J Am Soc Nephrol. 2001;12:1549–1557
  30. Dinarello CA, Roubenoff RA. Mechanisms of loss of lean body mass in patients on chronic dialysis. Blood Purif. 1996;14:388–394
  31. Flores EA, Bistrian BR, Pomposelli JJ, et al.  Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat (A synergistic effect with interleukin 1). J Clin Invest. 1989;83:1614–1622
  32. Tsujinaka T, Fujita J, Ebisui C, et al.  Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97:244–249
  33. Shaw JH, Wildbore M, Wolfe RR. Whole body protein kinetics in severely septic patients (The response to glucose infusion and total parenteral nutrition). Ann Surg. 1987;205:288–294
  34. Neyra R, Chen KY, Sun M, et al.  Increased resting energy expenditure in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr. 2003;27:36–42
  35. Ikizler TA, Pupim RB, Brouillette JR, et al.  Hemodialysis stimulates muscle and whole-body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab. 2002;282:E107–E116
  36. Ikizler TA, Wingard RL, Sun M, et al.  Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol. 1996;7:2646–2653
  37. Don BR, Rosales LM, Levine NW, et al.  Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int. 2001;59:1114–1120
  38. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  39. Stenvinkel P, Barany P, Heimburger O, et al.  Mortality, malnutrition, and atherosclerosis in ESRD (What is the role of interleukin-6?). Kidney Int. 2002;61:103–108
  40. Yudkin JS, Kumari M, Humphries SE, et al.  Inflammation, obesity, stress and coronary heart disease (Is interleukin-6 the link?). Atherosclerosis. 2000;148:209–214
  41. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality (Is C-reactive protein the missing link?). Kidney Int. 2001;59:407–414
  42. Himmelfarb J, Stenvinkel P, Ikizler TA, et al.  The elephant in uremia, Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538
  43. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37:S66–S70
  44. Ikizler TA, Greene JH, Wingard RL, et al.  Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int 57. 1996;50(suppl):S53–S56
  45. Cockram DB, Hensley MK, Rodriguez M, et al.  Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. J Ren Nutr. 1998;8:25–33
  46. Hecking E, Kohler H, Zobel R, et al.  Treatment with essential amino acids in patients on chronic hemodialysis (A double blind cross-over study). Am J Clin Nutr. 1978;31:1821–1826
  47. Phillips ME, Havard J, Howard JP. Oral essential amino acid supplementation in patients on maintenance hemodialysis. Clin Nephrol. 1978;9:241–248
  48. Eustace JA, Coresh J, Kutchey C, et al.  Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int. 2000;57:2527–2538
  49. Caglar K, Fedje L, Dimmitt R, et al.  Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int. 2002;
  50. Caglar K, Fedje L, Dimmitt R, et al.  Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int. 2002;62:1054–1059
  51. Cano N, Labastie-Coeyrehourq J, Lacombe P, et al.  Perdialytic parenteral nutrition with lipids and amino acids in malnourished hemodialysis patients. Am J Clin Nutr. 1990;52:726–730
  52. Heidland A, Kult J. Long-term effects of essential amino acids supplementation in patients on regular dialysis treatment. Clin Nephrol. 1975;3:234–239
  53. Pupim LB, Flakoll PJ, Brouillette JR, et al.  Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest. 2002;110:483–492
  54. Chertow GM, Ling J, Lew NL, et al.  The association of intradialytic parenteral nutrition with survival in hemodialysis patients. Am J Kidney Dis. 1994;24:912–920
  55. Mortelmans AK, Duym P, Vanderbroucke J, et al.  Intradialytic parenteral nutrition in malnourished hemodialysis patients (A prospective long-term study). JPEN J Parenter Enteral Nutr. 1999;23:90–95
  56. Jones M, Hagen T, Boyle CA, et al.  Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution (Results of a multicenter outpatient study). Am J Kidney Dis. 1998;32:761–769
  57. Kopple JD, Bernard D, Messana J, et al.  Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. 1995;47:1148–1157
  58. Palinski W, Tsimikas S. Immunomodulatory effects of statins (Mechanisms and potential impact on arteriosclerosis). J Am Soc Nephrol. 2002;13:1673–1681
  59. Seliger SL, Weiss NS, Gillen DL, et al.  HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304
  60. Boaz M, Smetana S, Weinstein T, et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) (Randomised placebo-controlled trial). Lancet. 2000;356:1213–1218

☆ This work was supported in part by NIH Grants #R01 45604 and #1K24 DK62849, FDA Grant #000943, the SatelliteHealth Extramural Grant Program, Clinical Nutrition Research Unit Grant #DK-26657, and General Clinical Research Center Grant #RR 00095.

PII: S1073-4449(04)00009-3

doi: 10.1053/j.arrt.2004.01.008

Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 162-171 , April 2004

Article Tools

* Image Usage & Resolution